Loading...
U.S. exports of cell cultures, whether or not modified (nesoi) (HS 300259) totaled $8.0M in July 2026.
Importers of Cell Cultures, Whether or Not Modified (NESOI) paid $6K in duties in July 2026 — an effective duty rate of 7.0% on $84K in dutiable value, based on actual customs collections rather than the published tariff schedule.
Last updated: July 2026 dataModified and unmodified cell cultures not classified under the dedicated cell-therapy heading serve as critical upstream inputs for vaccine production, biopharmaceutical manufacturing, and research applications. The United Kingdom and Germany are the leading US suppliers, with Switzerland and China also significant sources — a supplier mix that spans both highly regulated European GMP environments and lower-cost Asian production. Imported cell cultures may be subject to FDA review as biologics or research materials depending on their intended use, and APHIS may assert jurisdiction over cultures derived from animal or plant material. Classification between this heading (3002590000) and related Chapter 38 research-reagent provisions can be a recurring customs dispute for importers.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
232 shipments/mo
The key distinction is whether the cell culture is intended for therapeutic, prophylactic, or diagnostic use in humans or animals (Chapter 30) versus purely industrial or research use (Chapter 38). FDA-regulated biologics and products destined for clinical use generally belong in Chapter 30, while research-grade cell lines without a therapeutic indication may fall in Chapter 38. Importers should document the intended use clearly and consult a licensed customs broker, as CBP has issued binding rulings on this boundary.
Yes. Cell cultures derived from animal tissue may be subject to USDA APHIS review under the Animal Health Protection Act, particularly if there is a risk of introducing foreign animal disease agents. Importers may need to obtain an APHIS import permit and provide documentation of the source species, country of origin, and any pathogen-inactivation steps. This requirement is separate from FDA's biologics review.
HSChapter 30
Subheading 9 of 10 in heading 3002
Subheading 300259 · $3.6M of $7.4B
Supplier Network
Get discovered by U.S. importers searching for HS 300259 — Cell Cultures, Whether or Not Modified (NESOI). Be the first supplier listed.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Import Value | Effective Tariff % | Dutiable Share | Duty Collected |
|---|---|---|---|---|---|
| 3002590000 | Cell Cultures, Whether or not Modified, NESOI | $3.3M | 0.05% | 0.54% | $2K |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3002590000 | Cell Cultures, Whether or not Modified, NESOI | $8.8M |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
ImportsExports
Imports
$3.6MYoY · Pro
Exports
$8.0MYoY · Pro
12-mo low · imports
YoY · ProThrough July 2026. Source: U.S. Census Bureau.
Exports · July 2026
destination
customs district
origin
entry
rate provision · imports
97.7% enters free of duty; the effective duty rate is 0.16%.